Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
DOI:
https://doi.org/10.2340/actadv.v103.12314Keywords:
atopic dermatitis, IgE, biological agents, type 2 inflammatory diseasesAbstract
Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic approach, method to assess severity, and patient follow-up for this condition. An expert consensus study was conducted to provide recommendations on the management of patients with moderate-to-severe atopic dermatitis. The study used Delphi-like methodology based on a literature review, a summary of the scientific evidence, and a 2-round survey. The agreement of 60 panellists on 21 statements was evaluated. Consensus was pre-defined as ≥ 80% agreement of all respondents. In the first round 6 statements reached consensus. Unanimous consensus was achieved regarding therapeutic goals and patient satisfaction (maintained in the long term and periodic goals reassessment recommended every 3–6 months). In the second round, half of the statements reached consensus, all related to patient follow-up, treatment goals, and atopic comorbidities. The statements that did not reach consensus were related to diagnosis (biomarkers, allergy, and food testing) and starting patients on conventional systemic treatment rather than advanced treatment. The study assessed expert opinion regarding a variety of topics related to the clinical approach to patients with moderate-to-severe atopic dermatitis, in order to provide guidance on the diagnosis and management of patients with atopic dermatitis.
Downloads
References
Nettis E, Patella V, Lombardo C, Detoraki A, Macchia L, Di Leo E, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. Allergy 2020; 75: 2653-2661.
https://doi.org/10.1111/all.14338 DOI: https://doi.org/10.1111/all.14338
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70: 338-351.
https://doi.org/10.1016/j.jaad.2013.10.010 DOI: https://doi.org/10.1016/j.jaad.2013.10.010
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015; 66: 8-16.
https://doi.org/10.1159/000370220 DOI: https://doi.org/10.1159/000370220
Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126: 417-428.e412.
https://doi.org/10.1016/j.anai.2020.12.020 DOI: https://doi.org/10.1016/j.anai.2020.12.020
Sicras-Mainar A, Navarro-Artieda R, Sánchez L, Sastre J. Prevalence of severe atopic dermatitis in adults in 3 areas of Spain. J Investig Allergol Clin Immunol 2018; 28: 195-197.
https://doi.org/10.18176/jiaci.0234 DOI: https://doi.org/10.18176/jiaci.0234
Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol 2014; 5: 202.
Serra-Baldrich E, de Frutos JO, Jáuregui I, Armario-Hita JC, Silvestre JF, Herraez L, et al. Changing perspectives in atopic dermatitis. Allergol Immunopathol (Madr) 2018; 46: 397-412.
https://doi.org/10.1016/j.aller.2017.07.002 DOI: https://doi.org/10.1016/j.aller.2017.07.002
Senna G, Micheletto C, Piacentini G, Schiappoli M, Girolomoni G, Sala G, et al. Multidisciplinary management of type 2 inflammatory diseases. Multidiscip Respir Med 2022; 17: 813.
https://doi.org/10.4081/mrm.2022.813 DOI: https://doi.org/10.4081/mrm.2022.813
Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov 2022; 2: 100131.
https://doi.org/10.1016/j.xjidi.2022.100131 DOI: https://doi.org/10.1016/j.xjidi.2022.100131
Wise SK, Laury AM, Katz EH, Den Beste KA, Parkos CA, Nusrat A. Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression. Int Forum Allergy Rhinol 2014; 4: 361-370.
https://doi.org/10.1002/alr.21298 DOI: https://doi.org/10.1002/alr.21298
Humeniuk P, Dubiela P, Hoffmann-Sommergruber K. Dendritic cells and their role in allergy: uptake, proteolytic processing and presentation of allergens. Int J Mol Sci 2017; 18: 1491.
https://doi.org/10.3390/ijms18071491 DOI: https://doi.org/10.3390/ijms18071491
Weston W, Howe W. Atopic dermatitis (eczema): pathogenesis, clinical manifestations, and diagnosis. 2022. [cited 2022 Oct 5]. Available from: https://www.uptodate.com/
Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448-456.e430.
https://doi.org/10.1016/j.jaad.2018.03.017 DOI: https://doi.org/10.1016/j.jaad.2018.03.017
Hong MR, Lei D, Yousaf M, Chavda R, Gabriel S, Janmohamed SR, et al. A real-world study of the longitudinal course of adult atopic dermatitis severity in clinical practice. Ann Allergy Asthma Immunol 2020; 125: 686-692.e3.
https://doi.org/10.1016/j.anai.2020.07.005 DOI: https://doi.org/10.1016/j.anai.2020.07.005
Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol 2021; 147: 1174-1190.e1.
https://doi.org/10.1016/j.jaci.2021.01.013 DOI: https://doi.org/10.1016/j.jaci.2021.01.013
Mastraftsi S, Vrioni G, Bakakis M, Nicolaidou E, Rigopoulos D, Stratigos AJ, et al. Atopic dermatitis: striving for reliable biomarkers. J Clin Med 2022; 11: 4639.
https://doi.org/10.3390/jcm11164639 DOI: https://doi.org/10.3390/jcm11164639
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19: 15.
https://doi.org/10.1186/s12895-019-0095-3 DOI: https://doi.org/10.1186/s12895-019-0095-3
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345-360.
https://doi.org/10.1016/S0140-6736(20)31286-1 DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008-1015.
https://doi.org/10.1046/j.1365-2648.2000.t01-1-01567.x DOI: https://doi.org/10.1046/j.1365-2648.2000.t01-1-01567.x
Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club 1995; 123: A12-13.
https://doi.org/10.7326/ACPJC-1995-123-3-A12 DOI: https://doi.org/10.7326/ACPJC-1995-123-3-A12
Iannone M, Tonini G, Janowska A, Dini V, Romanelli M. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. Curr Med Res Opin 2021; 37: 1295-1301.
https://doi.org/10.1080/03007995.2021.1933929 DOI: https://doi.org/10.1080/03007995.2021.1933929
Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol 2015; 15: 453-460.
https://doi.org/10.1097/ACI.0000000000000198 DOI: https://doi.org/10.1097/ACI.0000000000000198
Spergel JM. Role of allergy in atopic dermatitis (eczema). online] 2022 [cited 2022 Oct 13]. Available from: https://www.uptodate.com/contents/role-of-allergy-in-atopic-dermatitis-eczema?search=atopic%20dermatitis&topicRef=1729&source=see_link#H1.
Hamann CR, Hamann D, Egeberg A, Johansen JD, Silverberg J, Thyssen JP. Association between atopic dermatitis and contact sensitization: a systematic review and meta-analysis. J Am Acad Dermatol 2017; 77: 70-78.
https://doi.org/10.1016/j.jaad.2017.02.001 DOI: https://doi.org/10.1016/j.jaad.2017.02.001
Schäfer T. The impact of allergy on atopic eczema from data from epidemiological studies. Curr Opin Allergy Clin Immunol 2008; 8: 418-422.
https://doi.org/10.1097/ACI.0b013e32830e71a7 DOI: https://doi.org/10.1097/ACI.0b013e32830e71a7
Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004; 114: 150-158.
https://doi.org/10.1016/j.jaci.2004.04.027 DOI: https://doi.org/10.1016/j.jaci.2004.04.027
Eller E, Kjaer HF, Høst A, Andersen KE, Bindslev-Jensen C. Food allergy and food sensitization in early childhood: results from the DARC cohort. Allergy 2009; 64: 1023-1029.
https://doi.org/10.1111/j.1398-9995.2009.01952.x DOI: https://doi.org/10.1111/j.1398-9995.2009.01952.x
Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database Syst Rev 2008; 2008: Cd005203.
https://doi.org/10.1002/14651858.CD005203.pub2 DOI: https://doi.org/10.1002/14651858.CD005203.pub2
Uenishi T, Sugiura H, Tanaka T, Uehara M. Role of foods in irregular aggravation of skin lesions in children with atopic dermatitis. J Dermatol 2008; 35: 407-412.
https://doi.org/10.1111/j.1346-8138.2008.00494.x DOI: https://doi.org/10.1111/j.1346-8138.2008.00494.x
Lim NR, Lohman ME, Lio PA. The role of elimination diets in atopic dermatitis - a comprehensive review. Pediatr Dermatol 2017; 34: 516-527.
https://doi.org/10.1111/pde.13244 DOI: https://doi.org/10.1111/pde.13244
Sastre J, Baldrich ES, Armario Hita JC, Herráez L, Jáuregui I, Martín-Santiago A, et al. Consensus on the clinical approach to moderate-to-severe atopic dermatitis in Spain: a Delphi survey. Dermatol Res Pract 2020; 2020: 1524293.
https://doi.org/10.1155/2020/1524293 DOI: https://doi.org/10.1155/2020/1524293
Perälä M, Ahola M, Mikkola T, Pelkonen AS, Remitz A, Mäkelä MJ. Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids. Acta Paediatr 2020; 109: 550-556.
https://doi.org/10.1111/apa.15001 DOI: https://doi.org/10.1111/apa.15001
Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatol Alergol 2019; 36: 752-759.
https://doi.org/10.5114/ada.2019.91425 DOI: https://doi.org/10.5114/ada.2019.91425
Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol 2016; 75: 410-419.e413.
https://doi.org/10.1016/j.jaad.2016.02.1228 DOI: https://doi.org/10.1016/j.jaad.2016.02.1228
Musters AH, Mashayekhi S, Harvey J, Axon E, Lax SJ, Flohr C, et al. Phototherapy for atopic eczema. Cochrane Database Syst Rev 2021; 10: Cd013870.
https://doi.org/10.1002/14651858.CD013870 DOI: https://doi.org/10.1002/14651858.CD013870
Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-1193.
https://doi.org/10.1111/j.1468-3083.2012.04636.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04636.x
Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Ruiz-Villaverde R, Vilar-Palomo S, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life (Basel) 2021; 11: 927.
https://doi.org/10.3390/life11090927 DOI: https://doi.org/10.3390/life11090927
European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. [cited 2022 Dec 20]. Available from https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki.
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402.
https://doi.org/10.2340/00015555-3751 DOI: https://doi.org/10.2340/00015555-3751
Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract 2021; 9: 1212-1223.e6.
https://doi.org/10.1016/j.jaip.2020.12.059 DOI: https://doi.org/10.1016/j.jaip.2020.12.059
Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy 2021; 51: 915-931.
https://doi.org/10.1111/cea.13954 DOI: https://doi.org/10.1111/cea.13954
Published
How to Cite
License
Copyright (c) 2023 Jose J. Pereyra-Rodriguez, Esther S. Baldrich, Ricardo Ruiz-Villaverde, Eulalia B. Torres, Pablo de la C. Dobao, Ignasi F. Nart, Ángeles F. Menéndez, Ana Martin-Santiago, Javier M. Miquel, Juan F. Silvestre, Jose C. Armario-Hita
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
